Phaseline

Targets › RHBDF2

RHBDF2 (Inactive rhomboid protein 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Feb 2028.

Regulates ADAM17 protease, a sheddase of the epidermal growth factor (EGF) receptor ligands and TNF, thereby plays a role in sleep, cell survival, proliferation, migration and inflammation. Does not exhibit any protease activity on its own. (UniProt, Q6PJF5)

Open in Phaseline: the race on RHBDF2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SciRhomSR-878
iRhom2 (RHBDF2) inhibitor
RHBDF2Phase 1Rheumatoid ArthritisFeb 2028

Conditions

Rheumatoid Arthritis (1)

Modalities

small molecule (1)

Companies

SciRhom (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.